Amgen Inc. (AMG HM) stock market data APIs
€246.5242
-10.78(-4.4%)
as of July 1, 2025
Try our APIs with
free plan!
Amgen Inc. Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for AMG.HM.
Prev. Close
246.5242
Open
235.7445
High
246.5242
Low
235.7445
52 wk Range
228.952-302.9209
Market Cap
105 182 M
Dividends (Yield)
0.0225
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Amgen Inc. data using free add-ons & libraries
Get Amgen Inc. Fundamental Data
Amgen Inc. Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Amgen Inc. News
New
Trading Rotation Kicks Off 2nd Half of 2025
Tuesday, July 1, 2025 Markets were mixed on this first trading day of July, kicking off a holiday-shortened week. Off successive all-time closing highs on the S&P 500 and Nasdaq, both took a breath...
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
Amgen (AMGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past...
Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?
Protagonist Therapeutics is taking aim directly at Eli Lilly's obesity treatment with a newly announced drug that uses the same mechanism. Continue Reading View Comments
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER
At an Interim Analysis, Bemarituzumab Plus Chemotherapy Significantly Improved Overall Survival in People With FGFR2b Overexpression Compared to Chemotherapy Alone THOUSAND OAKS, Calif., June 30, 202...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
